Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19

DOI record: { "DOI": "10.1038/s41598-025-85677-w", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-025-85677-w", "alternative-id": [ "85677" ], "article-number": "11022", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "2 August 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "6 January 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "31 March 2025" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Jia", "given": "Bohan", "sequence": "first" }, { "affiliation": [], "family": "Sun", "given": "Junyi", "sequence": "additional" }, { "affiliation": [], "family": "Zhu", "given": "Di", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Ling", "sequence": "additional" }, { "affiliation": [], "family": "Hu", "given": "Xiaobo", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Haiyu", "sequence": "additional" }, { "affiliation": [], "family": "Qian", "given": "Guowu", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Donghua", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Silin", "sequence": "additional" }, { "affiliation": [], "family": "Luo", "given": "Hong", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Shixi", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Guotao", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Guangming", "sequence": "additional" }, { "affiliation": [], "family": "Liang", "given": "Hongxia", "sequence": "additional" }, { "affiliation": [], "family": "Yu", "given": "Zujiang", "sequence": "additional" }, { "affiliation": [], "family": "Ren", "given": "Zhigang", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2025, 3, 31 ] ], "date-time": "2025-03-31T19:42:46Z", "timestamp": 1743450166000 }, "deposited": { "date-parts": [ [ 2025, 3, 31 ] ], "date-time": "2025-03-31T19:43:48Z", "timestamp": 1743450228000 }, "funder": [ { "DOI": "10.13039/501100012166", "award": [ "2023YFC3043514", "2022YFC2303100" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/501100012166", "id-type": "DOI" } ], "name": "National Key Research and Development Program of China" }, { "award": [ "ZYCXTD2023002", "QNCXTD2023002" ], "name": "Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University" }, { "name": "2024 Special Project of the National Key Laboratory of Innovative Drugs for Antiviral Infectious Diseases" } ], "indexed": { "date-parts": [ [ 2025, 3, 31 ] ], "date-time": "2025-03-31T20:10:22Z", "timestamp": 1743451822445, "version": "3.40.3" }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2025, 3, 31 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2025, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 3, 31 ] ], "date-time": "2025-03-31T00:00:00Z", "timestamp": 1743379200000 } }, { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 3, 31 ] ], "date-time": "2025-03-31T00:00:00Z", "timestamp": 1743379200000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-025-85677-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-025-85677-w", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-025-85677-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2025, 3, 31 ] ] }, "published-online": { "date-parts": [ [ 2025, 3, 31 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1002/cncr.33587", "author": "F Bray", "doi-asserted-by": "crossref", "first-page": "3029", "journal-title": "Cancer", "key": "85677_CR1", "unstructured": "Bray, F., Laversanne, M., Weiderpass, E. & Soerjomataram, I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127, 3029–3030 (2021).", "volume": "127", "year": "2021" }, { "DOI": "10.3322/caac.21660", "author": "H Sung", "doi-asserted-by": "crossref", "first-page": "209", "journal-title": "Cancer J. Clin.", "key": "85677_CR2", "unstructured": "Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71, 209–249 (2021).", "volume": "71", "year": "2021" }, { "DOI": "10.1016/S0140-6736(13)62224-2", "author": "P Vineis", "doi-asserted-by": "crossref", "first-page": "549", "journal-title": "Lancet", "key": "85677_CR3", "unstructured": "Vineis, P. & Wild, C. P. Global cancer patterns: causes and prevention. Lancet 383, 549–557 (2014).", "volume": "383", "year": "2014" }, { "DOI": "10.1053/j.seminoncol.2015.05.003", "author": "D Pardoll", "doi-asserted-by": "crossref", "first-page": "523", "journal-title": "Semin. Oncol.", "key": "85677_CR4", "unstructured": "Pardoll, D. Cancer and the immune system: basic concepts and targets for intervention. Semin. Oncol. 42, 523–538 (2015).", "volume": "42", "year": "2015" }, { "DOI": "10.1016/j.jaut.2017.07.010", "author": "A Sica", "doi-asserted-by": "crossref", "first-page": "117", "journal-title": "J. Autoimmun.", "key": "85677_CR5", "unstructured": "Sica, A. & Massarotti, M. Myeloid suppressor cells in cancer and autoimmunity. J. Autoimmun. 85, 117–125 (2017).", "volume": "85", "year": "2017" }, { "DOI": "10.1016/S0140-6736(20)31173-9", "author": "LY Lee", "doi-asserted-by": "crossref", "first-page": "1919", "journal-title": "Lancet (Lond. Engl.)", "key": "85677_CR6", "unstructured": "Lee, L. Y. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (Lond. Engl.) 395, 1919–1926 (2020).", "volume": "395", "year": "2020" }, { "DOI": "10.1016/S1470-2045(09)70069-5", "author": "M Kamboj", "doi-asserted-by": "crossref", "first-page": "589", "journal-title": "Lancet Oncol.", "key": "85677_CR7", "unstructured": "Kamboj, M. & Sepkowitz, K. A. Nosocomial infections in patients with cancer. Lancet Oncol. 10, 589–597 (2009).", "volume": "10", "year": "2009" }, { "DOI": "10.1038/s41579-021-00630-8", "author": "H Yang", "doi-asserted-by": "crossref", "first-page": "685", "journal-title": "Nat. Rev. Microbiol.", "key": "85677_CR8", "unstructured": "Yang, H. & Rao, Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 19, 685–700 (2021).", "volume": "19", "year": "2021" }, { "DOI": "10.1038/s41579-020-00468-6", "author": "P V’kovski", "doi-asserted-by": "crossref", "first-page": "155", "journal-title": "Nat. Rev. Microbiol.", "key": "85677_CR9", "unstructured": "V’kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).", "volume": "19", "year": "2021" }, { "DOI": "10.1056/NEJMoa2002032", "author": "WJ Guan", "doi-asserted-by": "crossref", "first-page": "1708", "journal-title": "N. Engl. J. Med.", "key": "85677_CR10", "unstructured": "Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1016/S1470-2045(20)30096-6", "author": "W Liang", "doi-asserted-by": "crossref", "first-page": "335", "journal-title": "Lancet Oncol.", "key": "85677_CR11", "unstructured": "Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337 (2020).", "volume": "21", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.03.296", "author": "L Zhang", "doi-asserted-by": "crossref", "first-page": "894", "journal-title": "Ann. Oncol.", "key": "85677_CR12", "unstructured": "Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. 31, 894–901 (2020).", "volume": "31", "year": "2020" }, { "DOI": "10.1056/NEJMoa2118542", "author": "J Hammond", "doi-asserted-by": "crossref", "first-page": "1397", "journal-title": "N Engl. J. Med.", "key": "85677_CR13", "unstructured": "Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl. J. Med. 386, 1397–1408 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1093/cid/ciac443", "author": "R Najjar-Debbiny", "doi-asserted-by": "crossref", "first-page": "e342", "journal-title": "Clin. Infect. Dis.", "key": "85677_CR14", "unstructured": "Najjar-Debbiny, R. et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis. 76, e342–e349 (2023).", "volume": "76", "year": "2023" }, { "DOI": "10.1021/acs.jmedchem.0c00940", "author": "L Sun", "doi-asserted-by": "crossref", "first-page": "8554", "journal-title": "J. Med. Chem.", "key": "85677_CR15", "unstructured": "Sun, L. et al. Mechanistic insight into antiretroviral potency of 2’-deoxy-2’-β-fluoro-4’-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention. J. Med. Chem. 63, 8554–8566 (2020).", "volume": "63", "year": "2020" }, { "key": "85677_CR16", "unstructured": "National Medical Products Administratior. The National Medical Products Administration has conditionally approved the marketing of Azvudine Tablets (2024, accessed 26 Dec 2024). https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20210721142223181.html." }, { "author": "Z Ren", "first-page": "e2001435", "journal-title": "Adv. Sci. (Weinh.)", "key": "85677_CR17", "unstructured": "Ren, Z. et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv. Sci. (Weinh.) 7, e2001435 (2020).", "volume": "7", "year": "2020" }, { "DOI": "10.1038/s41392-021-00835-6", "author": "JL Zhang", "doi-asserted-by": "crossref", "first-page": "414", "journal-title": "Signal. Transduct. Target. Therapy", "key": "85677_CR18", "unstructured": "Zhang, J. L. et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal. Transduct. Target. Therapy 6, 414 (2021).", "volume": "6", "year": "2021" }, { "DOI": "10.1158/2159-8290.CD-20-0422", "author": "M Dai", "doi-asserted-by": "crossref", "first-page": "783", "journal-title": "Cancer Discov.", "key": "85677_CR19", "unstructured": "Dai, M. et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 10, 783–791 (2020).", "volume": "10", "year": "2020" }, { "DOI": "10.1016/j.jinf.2020.04.006", "author": "J Ma", "doi-asserted-by": "crossref", "first-page": "318", "journal-title": "J. Infect.", "key": "85677_CR20", "unstructured": "Ma, J., Yin, J., Qian, Y. & Wu, Y. Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study. J. Infect. 81, 318–356 (2020).", "volume": "81", "year": "2020" }, { "DOI": "10.1002/rmv.2551", "author": "B Amani", "doi-asserted-by": "crossref", "first-page": "e2551", "journal-title": "Rev. Med. Virol.", "key": "85677_CR21", "unstructured": "Amani, B. & Amani, B. Azvudine versus paxlovid in COVID-19: a systematic review and meta-analysis. Rev. Med. Virol. 34, e2551 (2024).", "volume": "34", "year": "2024" }, { "DOI": "10.1371/journal.pone.0298772", "author": "B Amani", "doi-asserted-by": "crossref", "first-page": "e0298772", "journal-title": "PLoS One", "key": "85677_CR22", "unstructured": "Amani, B. & Amani, B. Effectiveness and safety of azvudine in COVID-19: a systematic review and meta-analysis. PLoS One 19, e0298772 (2024).", "volume": "19", "year": "2024" }, { "DOI": "10.7150/jca.91530", "author": "F Li", "doi-asserted-by": "crossref", "first-page": "2442", "journal-title": "J. Cancer", "key": "85677_CR23", "unstructured": "Li, F. et al. A retrospective analysis of azvudine in patients with COVID-19 and pre-existing cancer. J. Cancer 15, 2442–2447 (2024).", "volume": "15", "year": "2024" }, { "DOI": "10.21203/rs.3.rs-3876022/v1", "doi-asserted-by": "publisher", "key": "85677_CR24", "unstructured": "Guermazi, D., Arvanitis, P., Vieira, K., Warner, J. L. & Farmakiotis, D. Oral antivirals for COVID-19 among patients with cancer. Res. Square. https://doi.org/10.21203/rs.3.rs-3876022/v1 (2024)." }, { "DOI": "10.1038/s41467-019-09212-y", "author": "C Zhang", "doi-asserted-by": "crossref", "first-page": "1507", "journal-title": "Nat. Commun.", "key": "85677_CR25", "unstructured": "Zhang, C. et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat. Commun. 10, 1507 (2019).", "volume": "10", "year": "2019" }, { "author": "K Anwar", "first-page": "100452", "journal-title": "JTO Clin. Res. Rep.", "key": "85677_CR26", "unstructured": "Anwar, K., Nguyen, L., Nagasaka, M., Ou, S. H. I. & Chan, A. Overview of drug-drug interactions between ritonavir-boosted nirmatrelvir (paxlovid) and targeted therapy and supportive care for lung cancer. JTO Clin. Res. Rep. 4, 100452 (2023).", "volume": "4", "year": "2023" }, { "DOI": "10.1016/S0090-4295(99)00451-3", "author": "U Vaishampayan", "doi-asserted-by": "crossref", "first-page": "22", "journal-title": "Urology", "key": "85677_CR27", "unstructured": "Vaishampayan, U., Parchment, R. E., Jasti, B. R. & Hussain, M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54, 22–29 (1999).", "volume": "54", "year": "1999" }, { "DOI": "10.1016/S0022-3565(24)39081-0", "author": "D Yao", "doi-asserted-by": "crossref", "first-page": "387", "journal-title": "J. Pharmacol. Exp. Ther.", "key": "85677_CR28", "unstructured": "Yao, D., Ding, S., Burchell, B., Wolf, C. R. & Friedberg, T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J. Pharmacol. Exp. Ther. 294, 387–395 (2000).", "volume": "294", "year": "2000" }, { "DOI": "10.1016/j.infpip.2020.100061", "author": "M Tobaiqy", "doi-asserted-by": "crossref", "first-page": "100061", "journal-title": "Infect. Prev. Pract.", "key": "85677_CR29", "unstructured": "Tobaiqy, M. et al. Therapeutic management of patients with COVID-19: a systematic review. Infect. Prev. Pract. 2, 100061 (2020).", "volume": "2", "year": "2020" }, { "DOI": "10.1097/MD.0000000000021597", "author": "K Wang", "doi-asserted-by": "crossref", "first-page": "e21597", "journal-title": "Med. (Baltim).", "key": "85677_CR30", "unstructured": "Wang, K. et al. Therapeutic response to corticosteroids in a critically ill patient with COVID-19: a case report. Med. (Baltim). 99, e21597 (2020).", "volume": "99", "year": "2020" }, { "DOI": "10.1001/jama.2020.17023", "author": "WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group", "doi-asserted-by": "crossref", "first-page": "1330", "journal-title": "Jama", "key": "85677_CR31", "unstructured": "WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama 324, 1330–1341 (2020).", "volume": "324", "year": "2020" }, { "DOI": "10.1128/JVI.01702-07", "author": "K Jung", "doi-asserted-by": "crossref", "first-page": "13681", "journal-title": "J. Virol.", "key": "85677_CR32", "unstructured": "Jung, K. et al. Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus. J. Virol. 81, 13681–13693 (2007).", "volume": "81", "year": "2007" }, { "DOI": "10.1016/j.jcv.2004.07.006", "author": "N Lee", "doi-asserted-by": "crossref", "first-page": "304", "journal-title": "J. Clin. Virol.", "key": "85677_CR33", "unstructured": "Lee, N. et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J. Clin. Virol. 31, 304–309 (2004).", "volume": "31", "year": "2004" }, { "DOI": "10.3389/fphar.2020.01198", "author": "Y Ma", "doi-asserted-by": "crossref", "first-page": "1198", "journal-title": "Front. Pharmacol.", "key": "85677_CR34", "unstructured": "Ma, Y. et al. Corticosteroid use in the treatment of COVID-19: a Multicenter Retrospective Study in Hunan, China. Front. Pharmacol. 11, 1198 (2020).", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.eclinm.2023.101981", "author": "Y Sun", "doi-asserted-by": "crossref", "first-page": "101981", "journal-title": "EClinicalMedicine", "key": "85677_CR35", "unstructured": "Sun, Y. et al. Oral azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine 59, 101981 (2023).", "volume": "59", "year": "2023" } ], "reference-count": 35, "references-count": 35, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-025-85677-w" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy", "volume": "15" }